Health Economics›Breast cancer›Metastatic disease first-line chemotherapy

Metastatic disease first-line chemotherapy

Breast cancer · 41 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 30 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Paclitaxel, nanoparticle albumin-bound and Bevacizumab Variant #01	—	R 106 729	28d	9.3 mo	—	11	R 1 174 020 PFS proxy	2
nab-Paclitaxel monotherapy Variant #01	—	R 45 710	28d	6.9 mo	18.7 mo	8	R 365 679 PFS proxy	5
Paclitaxel and Bevacizumab Variant #01	—	R 40 037	28d	11.0 mo	28.5 mo	12	R 480 444 PFS proxy	6
Capecitabine and Paclitaxel, nanoparticle albumin-bound Variant #01	—	R 38 963	21d	—	—	—	—	—
FEC and Bevacizumab Variant #01	—	R 30 769	21d	9.2 mo	—	14	R 430 771 PFS proxy	1
Cyclophosphamide and Epirubicin (EC) and Bevacizumab Variant #01	—	R 30 701	21d	9.2 mo	—	14	R 429 809 PFS proxy	1
Docetaxel and Bevacizumab Variant #01	—	R 30 693	21d	9.7 mo	—	15	R 460 389 PFS proxy	2
Capecitabine and Bevacizumab Variant #01	—	R 29 610	21d	8.7 mo	26.1 mo	13	R 384 925 PFS proxy	2
FAC and Bevacizumab Variant #01	—	R 29 290	21d	9.2 mo	—	14	R 410 059 PFS proxy	1
Cyclophosphamide and Doxorubicin (AC) and Bevacizumab Variant #01	—	R 29 221	21d	9.2 mo	—	14	R 409 097 PFS proxy	1
Pegylated liposomal doxorubicin monotherapy Variant #01	—	R 15 300	28d	6.3 mo	—	7	R 107 100 PFS proxy	2
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	~4.6 mo	~11.0 mo	~3	~R 42 639 PFS proxy · indirect	16
Docetaxel and Gemcitabine Variant #01	—	R 4 912	21d	—	26.9 mo	—	—	2
Docetaxel and Epirubicin (DE) Variant #01	—	R 3 701	21d	—	—	—	—	—
Doxorubicin and Paclitaxel (AT) Variant #08	—	R 3 176	21d	—	25.3 mo	—	—	1
Epirubicin and Paclitaxel (EP) Variant #01	—	R 3 172	21d	10.8 mo	22.4 mo	16	R 50 755 PFS proxy	1
Capecitabine and Docetaxel (TX) Variant #01	—	R 3 056	21d	8.4 mo	—	13	R 39 725 PFS proxy	1
Epirubicin monotherapy Variant #01	—	R 2 611	21d	8.2 mo	19.1 mo	12	R 31 334 PFS proxy	—
Docetaxel and Doxorubicin (AT) Variant #01	—	R 2 548	21d	—	22.0 mo	—	—	1
Epirubicin and Vinorelbine (VE) Variant #01	—	R 2 445	21d	10.1 mo	—	15	R 36 668 PFS proxy	—
FEC Variant #01	—	R 2 364	21d	8.0 mo	19.2 mo	12	R 28 365 PFS proxy	1
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	6.9 mo	20.5 mo	8	R 17 756 PFS proxy	16
Paclitaxel monotherapy Variant #46	ERBB2	R 2 220	28d	6.9 mo	20.5 mo	8	R 17 756 PFS proxy	16
Capecitabine monotherapy Variant #17	—	R 2 219	21d	6.0 mo	—	9	R 19 974 PFS proxy	4
Capecitabine monotherapy Variant #17	ERBB2	R 2 219	21d	6.0 mo	—	9	R 19 974 PFS proxy	4
Capecitabine and Paclitaxel Variant #01	—	R 1 924	21d	—	—	—	—	—
Cyclophosphamide and Epirubicin (EC) Variant #01	—	R 1 775	21d	8.0 mo	20.3 mo	12	R 21 298 PFS proxy	1
Cyclophosphamide and Epirubicin (EC) Variant #01	ERBB2	R 1 775	21d	8.0 mo	20.3 mo	12	R 21 298 PFS proxy	1
Paclitaxel and Vinorelbine Variant #01	—	R 1 520	28d	—	—	—	—	—
Doxorubicin monotherapy Variant #10	—	R 1 293	21d	7.7 mo	13.8 mo	12	R 15 519 PFS proxy	1
FAC Variant #01	—	R 1 045	28d	8.0 mo	17.3 mo	9	R 9 409 PFS proxy	3
Cyclophosphamide and Doxorubicin (AC) Variant #01	—	R 718	21d	8.0 mo	20.3 mo	12	R 8 611 PFS proxy	1
Cyclophosphamide and Doxorubicin (AC) Variant #01	ERBB2	R 718	21d	8.0 mo	20.3 mo	12	R 8 611 PFS proxy	1
CMFT Variant #01	—	R 585	28d	—	—	—	—	—
CMF Variant #01	—	R 515	28d	—	21.5 mo	—	—	—
Gemcitabine and Paclitaxel N/A - secondary systemic drug	—	R 263	28d	6.5 mo	18.6 mo	8	R 2 108 PFS proxy	2
Docetaxel monotherapy N/A - secondary systemic drug	ERBB2	R 243	28d	8.2 mo	32.6 mo	9	R 2 188 PFS proxy	5
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	8.2 mo	32.6 mo	9	R 2 188 PFS proxy	5
Cyclophosphamide and Non-pegylated liposomal doxorubicin (MC) Variant #01 Partial	—	R 143	21d	—	—	—	—	—
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	~3.0 mo	~9.0 mo	~5	~R 347 PFS proxy · indirect	21
S-1 monotherapy Variant #01 Partial	—	—	21d	—	32.6 mo	—	—	2

41 of 41 regimens shown